Skip to main navigation Skip to main content

Clin Mol Hepatol : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Articles

Original Article

Cause of death and cause-specific mortality for primary liver cancer in South Korea: A nationwide population-based study in hepatitis B virus-endemic area

Clinical and Molecular Hepatology 2022;28(2):242-253.
Published online: February 7, 2022

1Department of Cancer Control and Population Health, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea

2Division of Gastroenterology, Department of Internal Medicine, Center for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang, Korea

3Division of Cancer Registration and Surveillance, National Cancer Control Institute, National Cancer Center, Goyang, Korea

Corresponding author : Hyunsoon Cho Department of Cancer Control and Population Health, National Cancer Center Graduate School of Cancer Science and Policy, 323 Ilsan-ro, Ilsandong-gu, Goyang 10408, Korea Tel: +82-31-920-2970 E-mail: hscho@ncc.re.kr

Editor: Young-Suk Lim, University of Ulsan College of Medicine, Korea

• Received: November 11, 2021   • Revised: January 19, 2022   • Accepted: February 4, 2022

Copyright © 2022 by The Korean Association for the Study of the Liver

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 12,439 Views
  • 156 Download
  • 26 Web of Science
  • 22 Crossref
  • 22 Scopus
prev next

Citations

Citations to this article as recorded by  Crossref logo
  • Causes of Death in Patients with Cancer: A Scoping Review
    Chien-Tzu Lee, Yifeng Gao, Volker Arndt
    Cancer Epidemiology, Biomarkers & Prevention.2026; 35(3): 379.     CrossRef
  • MicroRNA-206 suppresses hypoxia-inducible factor-1α/PFKFB3-mediated glycolysis to inhibit recurrence and metastasis of hepatocellular carcinoma after incomplete radiofrequency ablation
    Dong Lu, Li-Jun Wang, Jie Chai, Jun Jiang, Yan-Lin Tang
    World Journal of Gastrointestinal Oncology.2026;[Epub]     CrossRef
  • Mannose receptor-targeted MSC-derived exosomes as a high-affinity delivery platform for liver sinusoidal endothelial cells
    Ji Won Lee, Jin Suk Lee, Kangchan Choi, Mi Ra Lee, Seul Ki Han, Soon Koo Baik, Yong Serk Park, Moon Young Kim
    Drug Delivery and Translational Research.2026;[Epub]     CrossRef
  • Tenofovir Is Associated With a Better Prognosis Than Entecavir for Hepatitis B Virus–Related Hepatocellular Carcinoma
    Sung Won Chung, Hyun Jun Um, Won-Mook Choi, Jonggi Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee
    Clinical Gastroenterology and Hepatology.2025; 23(2): 300.     CrossRef
  • Survival Benefits of Transarterial Chemoembolization Plus Ablation Therapy in Patients With Intermediate or Advanced Hepatocellular Carcinoma: A Propensity Score Matching Study
    Jingyi Dai, Yadi Ding, Qiaomei Zheng, Guixin Zhao, Lingqing Zou, Jun Zhao, Yu Luo, Virasakdi Chongsuvivatwong
    Cancer Management and Research.2025; Volume 17: 483.     CrossRef
  • Bioactive Secondary Metabolites from Bauhinia variegata Linn. Roots: Isolation, Characterization, and Cytotoxic Evaluation
    Yousaf Kamal, Nighat Fatima, Amara Mumtaz, Irum Shahzadi, Abdul Mannan, Gerardo D. Anaya-Eugenio, Eric Daniel Salinas Arellano, Madiha Ahmed, Zahid Hussain, Esperanza J. Carcache de Blanco
    Current Pharmaceutical Design.2025; 31(15): 1239.     CrossRef
  • Pharmacological Evaluation of Angelica keiskei Extract: Molecular Interaction Analysis in Hepatocellular Carcinoma
    Alka Ashok Singh, Minseok Song, Gun-Do Kim
    Current Issues in Molecular Biology.2025; 47(6): 401.     CrossRef
  • Sex Disparity in Cancer and Non-cancer Mortality among Korean Cancer Survivors
    Ansun Jeong, Soyeoun Kim, Somin Jeon, Boyoung Park
    Journal of Cancer Prevention.2025; 30(4): 196.     CrossRef
  • Development and validation of a nomogram for predicting moderate-to-severe pain in hepatitis B virus-related liver cancer patients after CyberKnife treatment
    Yating Chi
    American Journal of Translational Research.2025; 17(9): 7058.     CrossRef
  • Association between Unplanned Conversion and Patient Survival after Laparoscopic Liver Resection for Hepatocellular Carcinoma: A Propensity Score Matched Analysis
    Boram Lee, Jai Young Cho, Ho-Seong Han, Yoo-Seok Yoon, Hae Won Lee, MeeYoung Kang, Yeshong Park, Jinju Kim
    Journal of Clinical Medicine.2024; 13(4): 1116.     CrossRef
  • Achieving Textbook Outcomes after Laparoscopic Resection in Posterosuperior Segments of the Liver: The Impact of the Learning Curve
    Mizelle D’Silva, Jai-Young Cho, Ho-Seong Han, Yoo-Seok Yoon, Hae-Won Lee, Bo-Ram Lee, Mee-Young Kang, Ye-Shong Park, Jin-Ju Kim
    Cancers.2024; 16(5): 930.     CrossRef
  • Organ‐specific responses to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma: A multicentre, retrospective study
    Jaekyung Cheon, Sanghoon Jung, Jung Sun Kim, Beodeul Kang, Hyeyoung Kim, Landon L. Chan, Lars Becker, Vincent E. Gaillard, Stephen L. Chan, Chan Kim, Hong Jae Chon
    Liver International.2024; 44(8): 1961.     CrossRef
  • Development and validation of a prognostic nomogram including inflammatory indicators for overall survival in hepatocellular carcinoma patients treated primarily with surgery or loco-regional therapy: A single-center retrospective study
    Xin Wang, Jing Xu, Zhenya Jia, Guoping Sun
    Medicine.2024; 103(50): e40889.     CrossRef
  • Development and validation of prognostic nomograms for large hepatocellular carcinoma after HAIC
    Wang Yao, Ran Wei, Jia Jia, Wang Li, Mengxuan Zuo, Shuqing Zhuo, Ge Shi, Peihong Wu, Chao An
    Therapeutic Advances in Medical Oncology.2023;[Epub]     CrossRef
  • Impact of sarcopenia on clinical outcomes for patients with resected hepatocellular carcinoma: a retrospective comparison of Eastern and Western cohorts
    Berend R. Beumer, Kosei Takagi, Stefan Buettner, Yuzo Umeda, Takahito Yagi, Toshiyoshi Fujiwara, Jeroen L.A. van Vugt, Jan N.M. IJzermans
    International Journal of Surgery.2023; 109(8): 2258.     CrossRef
  • Isolated Hepatitis B Core Antibody Positivity and Long-Term Liver-Related Mortality in Korea: A Cohort Study
    Won Sohn, Yoosoo Chang, Yong Kyun Cho, Yun Soo Hong, Seungho Ryu
    American Journal of Gastroenterology.2023; 118(1): 95.     CrossRef
  • Barriers to palliative care in hepatocellular carcinoma: A review of the literature
    Mostafa Abasseri, Shakira Hoque, BA Slavica Kochovska, Kim Caldwell, Linda Sheahan, Amany Zekry
    Journal of Gastroenterology and Hepatology.2023; 38(7): 1047.     CrossRef
  • Dihydrotanshinone I inhibits hepatocellular carcinoma cells proliferation through DNA damage and EGFR pathway
    Linjun Wang, Xiangwei Xu, Dexing Chen, Chenghang Li
    PeerJ.2023; 11: e15022.     CrossRef
  • Primary non-response to antiviral therapy affects the prognosis of hepatitis B virus-related hepatocellular carcinoma
    Peng Wang, Xinhui Wang, Xiaoli Liu, Fengna Yan, Huiwen Yan, Dongdong Zhou, Lihua Yu, Xianbo Wang, Zhiyun Yang
    BMC Cancer.2023;[Epub]     CrossRef
  • Identification of ELOVL3 as a novel prognostic marker for liver cancer
    Yiyang Chen, Wanbang Zhou, Yiju Gon, Xi Ou
    AFMN Biomedicine.2023; 40(3): 279.     CrossRef
  • Applications of molecular barcode sequencing for the detection of low‐frequency variants in circulating tumour DNA from hepatocellular carcinoma
    Hye Won Lee, Esl Kim, Kyung Joo Cho, Hye Jung Park, Jieun Seo, Hyeonah Lee, Eunha Baek, Jong Rak Choi, Kwang‐Hyub Han, Seung‐Tae Lee, Jun Yong Park
    Liver International.2022; 42(10): 2317.     CrossRef
  • Incidence, mortality, and survival of liver cancer using Korea central cancer registry database: 1999-2019
    Sung Yeon Hong, Mee Joo Kang, Taegyu Kim, Kyu-Won Jung, Bong-Wan Kim
    Annals of Hepato-Biliary-Pancreatic Surgery.2022; 26(3): 211.     CrossRef

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

Include:

Cause of death and cause-specific mortality for primary liver cancer in South Korea: A nationwide population-based study in hepatitis B virus-endemic area
Clin Mol Hepatol. 2022;28(2):242-253.   Published online February 7, 2022
Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:
Include:
Cause of death and cause-specific mortality for primary liver cancer in South Korea: A nationwide population-based study in hepatitis B virus-endemic area
Clin Mol Hepatol. 2022;28(2):242-253.   Published online February 7, 2022
Close

Figure

  • 0
  • 1
  • 2
  • 3
Cause of death and cause-specific mortality for primary liver cancer in South Korea: A nationwide population-based study in hepatitis B virus-endemic area
Image Image Image Image
Figure 1. Distribution of age and tumor stage at liver cancer diagnosis, 2000–2016. (A) By age group. (b) By tumor stage. Tumor stage information was available from 2006. Percentages are rounded to one decimal place.
Figure 2. Trends in proportionate mortalities in liver cancer patients, 2000–2016. (A) By the year of death. (B) By time since diagnosis. Percentages are rounded to one decimal place.
Figure 3. Survival and cause-specific competing risks probability of death, 2000–2016. (A) Five-year all-cause survival and cause-specific competing risks probability of death by tumor stage and year of diagnosis. (B) Competing risks probability of death from liver cancer and other-causes by age at diagnosis. Tumor stage information was available from 2006. The probability of death was estimated by the cumulative incidence function. Percentages are rounded to one decimal place.
Graphical abstract
Cause of death and cause-specific mortality for primary liver cancer in South Korea: A nationwide population-based study in hepatitis B virus-endemic area
Characteristic Total (n=231,388) Male (n=174,638) Female (n=56,750)
Age at diagnosis (years) 60.9±12.1 59.5±11.5 65.4±12.5
 20–39† 7,109 (3.1) 5,589 (3.2) 1,520 (2.7)
 40–49 34,601 (15.0) 29,658 (17.0) 4,943 (8.7)
 50–59 66,578 (28.8) 55,510 (31.8) 11,068 (19.5)
 60–69 63,813 (27.6) 47,588 (27.3) 16,225 (28.6)
 70–79 44,262 (19.1) 28,518 (16.3) 15,744 (27.7)
 ≥80 15,025 (6.5) 7,775 (4.5) 7,250 (12.8)
Alive† 51,467 (22.2) 38,772 (22.2) 12,695 (22.4)
Death† 179,921 (77.8) 135,866 (77.8) 44,055 (77.6)
Cause of death‡
 Liver cancer 166,167 (92.4) 125,530 (92.4) 40,637 (92.2)
 Cancer of other sites 3,007 (1.7) 2,136 (1.6) 871 (2.0)
 Non-cancer causes 10,747 (6.0) 8,200 (6.0) 2,547 (5.8)
Tumor type‡
 HCC 191,334 (82.7) 150,371 (86.1) 40,963 (72.2)
 ICCA 40,054 (17.3) 24,267 (13.9) 15,787 (27.8)
Tumor stage‡
 Localized 70,244 (30.4) 52,813 (30.2) 17,431 (30.7)
 Regional 36,450 (15.8) 28,310 (16.2) 8,140 (14.3)
 Distant 23,269 (10.1) 17,390 (10.0) 5,879 (10.4)
 Unknown/NA 101,425 (43.8) 76,125 (43.6) 25,300 (44.6)
Rank Total
Male
Female†
Cause of death Count‡ SMR§ (95% CI) Cause of death Count‡ SMR§ (95% CI) Cause of death Count‡ SMR§ (95% CI)
1 Diseases of liver∥ 3,707 (34.5) 15.6 (15.1–16.1) Diseases of liver∥ 2,905 (35.4) 9.7 (9.4–10.1) Diseases of liver∥ 802 (31.5) 28.2 (26.2–30.1)
2 Viral hepatitis 1,148 (10.7) 46.5 (43.9–49.2) Viral hepatitis 847 (10.3) 40.2 (37.5–42.9) Viral hepatitis 301 (11.8) 50.3 (44.6–56.0)
3 Cerebrovascular disease 802 (7.5) 0.7 (0.7–0.8) Intentional self-harm 656 (8.0) 2.1 (1.9–2.2) Cerebrovascular disease 225 (8.8) 0.7 (0.6–0.8)
4 Intentional self-harm 713 (6.6) 2.6 (2.4–2.8) Cerebrovascular disease 577 (7.0) 0.6 (0.6–0.7) Heart diseases 202 (7.9) 0.9 (0.8–1.0)
5 Heart diseases 665 (6.2) 0.8 (0.8–0.9) Heart diseases 463 (5.6) 0.7 (0.6–0.7) Diabetes mellitus 123 (4.8) 1.0 (0.8–1.2)
Characteristic Coefficient sHR (95% CI) P-value
Sex
 Female Reference
 Male 0.12 1.13 (1.11–1.15) <0.0001
Age at diagnosis (years)
 20–39 Reference
 40–49 0.06 1.07 (1.02–1.12) 0.0049
 50–59 0.01 1.02 (0.97–1.06) 0.4964
 60–69 0.11 1.11 (1.07–1.16) <0.0001
 70–79 0.39 1.48 (1.42–1.55) <0.0001
 ≥80 0.82 2.27 (2.16–2.39) <0.0001
Tumor type
 HCC Reference
 ICCA 0.18 1.20 (1.17–1.22) <0.0001
Stage
 Localized Reference
 Regional 0.88 2.42 (2.38–2.46) <0.0001
 Distant 1.49 4.45 (4.36–4.54) <0.0001
Year of diagnosis
 2006–2010 Reference
 2011–2016 -0.23 0.80 (0.79–0.81) <0.0001
Table 1. Demographics of patients diagnosed with primary liver cancer diagnosed between 2000 and 2016*

Values are presented as mean±standard deviation or number (%).

HCC, hepatocellular carcinoma; ICCA, intrahepatic cholangiocarcinoma; NA, not available.

Patients diagnosed with primary liver cancer from January 1, 2000 to December 31, 2016 who were followed up to December 31, 2017. Patients aged under 20 years at diagnosis were excluded. Tumor stage information was available only for 156,300 patients diagnosed with cancer from January 1, 2006 to December 31, 2016, among which 26,337 patients had unknown tumor stage (16.9%).

Percentage among total number of patients (all sex, male, or female) is presented.

Percentage among total number of deaths.

Table 2. Standard mortality ratios of non-cancer causes of death among liver cancer patients* relative to the Korean general population

Values are presented as number (%) unless otherwise indicated.

SMR, standard mortality ratio; CI, confidence interval.

Patients diagnosed with primary liver cancer from January 1, 2000 to December 31, 2016 who were followed up to December 31, 2017. Patients aged under 20 years at diagnosis were excluded.

SMR of intentional self-harm among female patients=1.4 (95% CI, 1.0–1.8).

Percentage among non-cancer deaths.

SMRs for the specific cause of death were calculated as the average ratio of observed deaths in cancer patients from 2000 to 2017 to the expected deaths in the general population from 2000 to 2017.

Second highest SMR among non-cancer cause of death (COD).

Highest SMR among non-cancer COD.

Table 3. A multivariable analysis estimating hazard of death from liver cancer under the presence of competing risks using the Fine-Gray model*

CI, confidence interval; HCC, hepatocellular carcinoma; ICCA, intrahepatic cholangiocarcinoma.

Patients diagnosed with primary liver cancer from January 1, 2006 to December 31, 2016, followed up to December 31, 2017, with tumor stage information available were included in the model. Patients who were aged under 20 years at diagnosis were excluded.